Literature DB >> 7898459

Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.

J vanderSpek1, L Cosenza, T Woodworth, J C Nichols, J R Murphy.   

Abstract

We have used protein engineering and recombinant DNA methodologies in order to construct a fusion protein in which human interleukin-2 (IL-2) is genetically linked to the catalytic and transmembrane domains of diphtheria toxin. The fusion toxin, DAB486IL-2, is highly cytotoxic for only those cells which display the high affinity interleukin-2 receptor (IL-2R) on their surface. In phase I/II clinical studies the intravenous administration of DAB486IL-2 has been found to be safe, well tolerated and may lead to the induction of durable remissions in patients presenting with a variety of IL-2R positive lymphomas.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7898459     DOI： 10.1007/bf00928457

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  31 in total

1.  The crystal structure of diphtheria toxin.

Authors:  S Choe; M J Bennett; G Fujii; P M Curmi; K A Kantardjieff; R J Collier; D Eisenberg
Journal:  Nature       Date:  1992-05-21       Impact factor: 49.962

2.  Diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion toxin. Internal in-frame deletion from Thr387 to His485 results in the formation of a highly potent fusion toxin which is resistant to proteolytic degradation.

Authors:  Z L Wen; X Tao; F Lakkis; T Kiyokawa; J R Murphy
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

3.  Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells.

Authors:  D P Williams; C E Snider; T B Strom; J R Murphy
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

4.  The human immune response to the OKT3 monoclonal antibody is oligoclonal.

Authors:  L Chatenoud; M Jonker; F Villemain; G Goldstein; J F Bach
Journal:  Science       Date:  1986-06-13       Impact factor: 47.728

Review 5.  Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS.

Authors:  E S Vitetta
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

6.  Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis.

Authors:  P Bacha; S E Forte; S J Perper; D E Trentham; J C Nichols
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

7.  Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.

Authors:  J P Shaw; D E Akiyoshi; D A Arrigo; A E Rhoad; B Sullivan; J Thomas; F S Genbauffe; P Bacha; J C Nichols
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

8.  Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells.

Authors:  T Kiyokawa; D P Williams; C E Snider; T B Strom; J R Murphy
Journal:  Protein Eng       Date:  1991-04

9.  Three-dimensional structure of interleukin-2.

Authors:  B J Brandhuber; T Boone; W C Kenney; D B McKay
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

10.  A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV.

Authors:  P Aullo; J Alcami; M R Popoff; D R Klatzmann; J R Murphy; P Boquet
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.